Biomind Labs Inc.
BMNDF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | -0.25 | 1.44 | -0.05 |
| FCF Yield | -3.18% | 0.25% | 0.00% | -0.43% |
| EV / EBITDA | 0.00 | -85.37 | -1,167.06 | -1,579.14 |
| Quality | ||||
| ROIC | 0.00% | 10.88% | 15.71% | 14.99% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.38 | -0.17 | -0.01 | -0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -298.46% | 4,210.31% | 100.44% | 7.62% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -6.58 | -13.35 | -43.19 |
| Interest Coverage | -4.52 | -5.12 | -6.55 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -12,982.55 | -22,430.62 |